Cancer Research Horizons Revenue and Competitors
Employee Data
- Cancer Research Horizons has 99 Employees.
- Cancer Research Horizons grew their employee count by 27% last year.
Cancer Research Horizons's People
Name | Title | Email/Phone |
---|
Cancer Research Horizons Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 119 | -4% | N/A | N/A |
#2 | $7.5M | 65 | 5% | N/A | N/A |
#3 | N/A | 238 | 23% | N/A | N/A |
#4 | N/A | 240 | 40% | N/A | N/A |
#5 | N/A | 37 | 147% | N/A | N/A |
#6 | $75M | 706 | 40% | N/A | N/A |
#7 | N/A | 318 | 36% | N/A | N/A |
#8 | $3.5M | 77 | 20% | N/A | N/A |
#9 | N/A | 25 | 67% | N/A | N/A |
#10 | $3.5M | 60 | 15% | N/A | N/A |
What Is Cancer Research Horizons?
Cancer Research Horizons is Cancer Research UK's innovation engine.\n\nWe take scientific breakthroughs from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients. \n\nTo date, we’ve played an instrumental role in forming over 60 spin-out companies and bringing 11 new cancer drugs to market, borne out of our pioneering research. We are the second biggest licensor of cancer research treatments globally and are part of Cancer Research UK – the world’s largest medical research charity. \n\nWith exclusive rights to over £300m of world-class cancer research we’re a unique and powerful partner in the fight to beat cancer. We work closely with academia and industry to bridge the gap between research and the market, delivering maximum impact for patients. Every penny we make goes back into developing the next breakthroughs, helping bring forward the day when all cancer is conquered.
keywords:N/AN/A
Total Funding
99
Number of Employees
N/A
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $11.9M | 99 | 2% | N/A |
#2 | $22.5M | 99 | -12% | N/A |
#3 | $20M | 99 | -17% | N/A |
#4 | $14.4M | 99 | -4% | N/A |
#5 | $23.7M | 99 | 9% | N/A |